Page last updated: 2024-09-05

troleandomycin and terazosin

troleandomycin has been researched along with terazosin in 2 studies

Compound Research Comparison

Studies (troleandomycin)	Trials (troleandomycin)	Recent Studies (post-2010) (troleandomycin)	Studies (terazosin)	Trials (terazosin)	Recent Studies (post-2010) (terazosin)
569	26	23	658	173	104

Protein Interaction Comparison

Protein	Taxonomy	terazosin (IC50)
Alpha-2B adrenergic receptor	Homo sapiens (human)	0.428
Alpha-2C adrenergic receptor	Homo sapiens (human)	6.042
Alpha-1D adrenergic receptor	Homo sapiens (human)	0.011
Alpha-1A adrenergic receptor	Homo sapiens (human)	0.005
Alpha-1B adrenergic receptor	Homo sapiens (human)	0.005

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Bae, SK; Kwon, JW; Lee, DC; Lee, MG; Oh, EY; You, M	1

Other Studies

2 other study(ies) available for troleandomycin and terazosin

Article	Year
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats. British journal of pharmacology, 2007, Volume: 151, Issue:1 Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Dexamethasone; Drug Interactions; Male; Membrane Proteins; Microsomes, Liver; Prazosin; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Troleandomycin	2007

Article

Year

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012

Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats.

British journal of pharmacology, 2007, Volume: 151, Issue:1

Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Dexamethasone; Drug Interactions; Male; Membrane Proteins; Microsomes, Liver; Prazosin; Pyrimidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Troleandomycin

2007